Hyperhomocysteinaemia Promotes Doxorubicin-Induced Cardiotoxicity in Mice
Doxorubicin, a widely used chemotherapeutic drug in clinical oncology, causes a series of cardiac side effects referred to as doxorubicin-induced cardiotoxicity. Hyperhomocysteinaemia is an independent risk factor for multiple cardiovascular diseases. However, whether hyperhomocysteinaemia contribut...
Main Authors: | Rui Fan, Yao Wang, Jinjin Zhang, Xiangbo An, Shuang Liu, Jie Bai, Jiatian Li, Qiuyue Lin, Yunpeng Xie, Jiawei Liao, Yunlong Xia |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-08-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/16/9/1212 |
Similar Items
-
A case report of branch retinal artery occlusion in a teenager due to hyperhomocysteinaemia; the interplay of genetic and nutritional defects
by: Clare Shute
Published: (2018-09-01) -
Indicators of mineral metabolism and dental status of young rats born from female with methionine-induced hyperhomocysteinemia
by: O. Kutelmakh, et al.
Published: (2021-12-01) -
Lipidomics application to explain acute cardiotoxicity induced by doxorubicin
by: Lubna Zuhair Abdul Karim, et al.
Published: (2019-12-01) -
Dapagliflozin May Protect Against Doxorubicin-Induced Cardiotoxicity
by: Sebahat Ulusan, et al.
Published: (2023-05-01) -
Investigation of the efficacy of tyrosol on doxorubicin-induced acute cardiotoxicity in rats
by: Mustafa Cellat, et al.
Published: (2022-09-01)